Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

145.68
-3.1800-2.14%
Post-market: 144.81-0.8700-0.60%19:46 EDT
Volume:3.95M
Turnover:576.00M
Market Cap:180.74B
PE:-55.71
High:149.47
Open:149.47
Low:144.88
Close:148.86
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.75
T/O Rate:0.32%
Dividend:3.22
Dividend Rate:2.21%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.28
PE(LYR):21.49

Loading ...

Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run

Simply Wall St.
·
Yesterday

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo

TIPRANKS
·
Aug 29

Gilead Breaks Ground on Foster City Biologics Facility in $32 Billion US Investment Push

Reuters
·
Aug 28

Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares

Reuters
·
Aug 28

Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV

TIPRANKS
·
Aug 28

US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment

Reuters
·
Aug 28

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens

THOMSON REUTERS
·
Aug 28

Moderna Inc. Stock Slips 4.6%, Underperforms Peers

Dow Jones
·
Aug 28

Moderna Inc. Stock Falls 5.8%, Underperforms Peers

Dow Jones
·
Aug 27

Gilead Sciences Updates Financial Calendar with Investor Conference Presentations

Reuters
·
Aug 27

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 26

Moderna Inc. Stock Rallies 14.4%, Outperforms Peers

Dow Jones
·
Aug 26

Moderna Inc. Stock Slides 4.3%, Underperforms Peers

Dow Jones
·
Aug 25

Lakefront Biotherapeutics Wins FDA Orphan Drug Status for Gamgertamig in Pemphigus

Reuters
·
Aug 25

EU Commission Approves Gilead Trodelvy-Keytruda Combo for First-Line PD-L1+ Metastatic TNBC

Reuters
·
Aug 24

Gilead - EU Grants Marketing Authorization for Trodelvy with Keytruda in First-Line Pd-L1-Positive Metastatic Tnbc

THOMSON REUTERS
·
Aug 24

European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across Pd-L1 Status

THOMSON REUTERS
·
Aug 24

Funds: What a Top Biotech Fund is Buying Now

Dow Jones
·
Aug 22

Gilead Director Jeffrey Bluestone Disposes of 5,000 Common Shares Worth $727,333.60

Reuters
·
Aug 22